drugset / Trial / NCT02595528

A Study of the Concurrent Use of AGN-190584 and AGN-199201 in Participants With Presbyopia

NCT02595528

Phase 2 Completed 163 enrolled Allergan
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will identify the optimum concentrations of AGN-199201 and AGN-190584 when dosed in combination once a day for the improvement of uncorrected near visual acuity in participants with presbyopia (inability to focus on items close-up).

Timeline

Start
2016-04-29
Primary completion
2017-10-18
Completion
2017-10-18

Drugs

EvaluationDrugModalityDoseRoute
Subject AGN-190584 Unknown Other
Subject Oxymetazoline Other / unclassified Other

Indications